Trial reportJournal of cosmetic dermatology2019
A novel moisturizer with high sun protection factor improves cutaneous barrier function and the visible appearance of rosacea-prone skin.
Trial report in Journal of cosmetic dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05961579 (A Prospective, Open Label Clinical Study Evaluating the Efficacy and Safety of Cleanser, Serum, and Sunscreen Products for the Treatment of Facial Redness.), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Open Label Clinical Study Evaluating the Efficacy and Safety of Cleanser, Serum, and Sunscreen Products for the Treatment of Facial Redness.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- A novel moisturizer with high sun protection factor improves cutaneous barrier function and the visible appearance of rosacea-prone skin.Journal of cosmetic dermatology · 2019Trial
- Risk factors for acne vulgaris among rosacea patients: a cross-sectional study.Frontiers in public health · 2026Article
- Rosacea Topical Treatment and Care: From Traditional to New Drug Delivery Systems.Molecular pharmaceutics · 2023Review
- Exploring the Pathogenesis and Mechanism-Targeted Treatments of Rosacea: Previous Understanding and Updates.Biomedicines · 2023Review
- Rosacea pathogenesis and therapeutics: current treatments and a look at future targets.Frontiers in medicine · 2023Review
- Impact of ultraviolet radiation and exposome on rosacea: Key role of photoprotection in optimizing treatment.Journal of cosmetic dermatology · 2021Review
- The Importance of Assessing Burning and Stinging when Managing Rosacea: A Review.Acta dermato-venereologica · 2021Review
- The Application of Skin Care Product in Melasma Treatment.Clinical, cosmetic and investigational dermatology · 2021Review
- A Preliminary Clinical Evaluation of a Topical Product for Reducing Slight Rosacea Imperfections.Clinical, cosmetic and investigational dermatology · 2020Article
- Clinical and in vitro evaluation of new anti-redness cosmetic products in subjects with winter xerosis and sensitive skin.International journal of cosmetic science · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundConsensus guidelines advocate general skincare for rosacea patients.
objectivesTwo independent studies were performed to assess whether a tinted daily SPF-30 facial moisturizer (DFM30) improves barrier function of dry skin and the efficacy and tolerability of DFM30 on rosacea-prone skin.
methodsIn study 1, electrical capacitance (EC) and transepidermal water loss (TEWL) were measured at baseline, 2, 4, 8, and 24 hours after a single application of DFM30 and on a control site in 21 healthy females with dry skin. Study 2 evaluated 33 females with mild to moderate rosacea and nontransient erythema. Efficacy and tolerability after once-daily DFM30 were assessed using a chromameter, image analysis of photographs, and trained rater and patient evaluations up to day 22.
resultsIn study 1, EC showed statistically significant increases at 2, 4, and 8 hours, and TEWL showed statistically significant decreases 2, 4, 8, and 24 hours after DFM30 application to healthy females compared to baseline. In study 2, covering skin redness improved significantly after DFM30 application on day 1; 33.3% showed improved covering skin redness compared to baseline. Patients reported significantly less redness on day 8 than day 3. Feelings of dryness and tightness/tension were lower 30 minutes after first application. Feeling of dryness was lower than baseline after 3 days, 1 and 3 weeks. Image analysis suggested redness was significantly lower on day 22 compared to baseline. Chromameter readings showed significantly lower erythema on the cheek compared to baseline. All patients stated that DFM30 relieves and neutralizes visible redness who also indicated that they would purchase DFM30, and the product was well tolerated.
conclusionsThese studies show that DFM30 is suitable as part of the skincare regimens advocated by ROSacea COnsensus (ROSCO) for rosacea patients. DFM30 is an effective moisturizer that improves cutaneous barrier function and the appearance of rosacea-prone skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.